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Abstract
Background: Implication of pharmacogenetic variations and efavirenz pharmacokinetics in concomitant efavirenz based
antiviral therapy and anti-tubercular drug induced liver injury (DILI) has not been yet studied. We performed a prospective
case-control association study to identify the incidence, pharmacogenetic, pharmacokinetic and biochemical predictors for
anti-tubercular and antiretroviral drugs induced liver injury (DILI) in HIV and tuberculosis (TB) co-infected patients.
Methods and Findings: Newly diagnosed treatment naı ¨ve TB-HIV co-infected patients (n=353) were enrolled to receive
efavirenz based ART and rifampicin based anti-TB therapy, and assessed clinically and biochemically for DILI up to 56 weeks.
Quantification of plasma efavirenz and 8-hydroxyefaviernz levels and genotyping for NAT2, CYP2B6, CYP3A5, ABCB1, UGT2B7
and SLCO1B1 genes were done. The incidence of DILI and identification of predictors was evaluated using survival analysis
and the Cox Proportional Hazards Model. The incidence of DILI was 30.0%, or 14.5 per 1000 person-week, and that of severe
was 18.4%, or 7.49 per 1000 person-week. A statistically significant association of DILI with being of the female sex
(p=0.001), higher plasma efavirenz level (p=0.009), efavirenz/8-hydroxyefavirenz ratio (p=0.036), baseline AST (p=0.022),
ALT (p=0.014), lower hemoglobin (p=0.008), and serum albumin (p=0.007), NAT2 slow-acetylator genotype (p=0.039)
and ABCB1 3435TT genotype (p=0.001).
Conclusion: We report high incidence of anti-tubercular and antiretroviral DILI in Ethiopian patients. Between patient
variability in systemic efavirenz exposure and pharmacogenetic variations in NAT2, CYP2B6 and ABCB1 genes determines
susceptibility to DILI in TB-HIV co-infected patients. Close monitoring of plasma efavirenz level and liver enzymes during
early therapy and/or genotyping practice in HIV clinics is recommended for early identification of patients at risk of DILI.
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Introduction
Tuberculosis (TB) is the most common opportunistic fatal
infection in HIV infected patients [1]. Concomitant HIV and TB
treatment is recommended in patients with low CD4 cell counts.
Although effective therapy is available for both TB and HIV,
concurrent treatment is complicated due to adverse drug reactions
[2]. Anti-tuberculosis and antiretroviral drug induced liver injury
(DILI), a common serious adverse drug reaction, is one of the most
challenging clinical problems, cause of hospitalization and life-
threatening events [3,4]. DILI can be fatal if therapy is not
interrupted on time, and the subsequent adherence problem may
cause treatment failure and, relapse or drug resistance [5–7]. The
reported incidence of DILI during TB treatment varies from 5 to
33% [5,6]. In patients receiving anti-retroviral therapy between
14–20% experience elevations of liver enzymes, and about 2–10%
need to interrupt anti-retroviral therapy due to severe hepatic
injury and marked elevation of liver enzymes [8,9].
Among the first-line TB drugs pyrazinamide, isoniazid and
rifampicin have all been associated with DILI [2]. All classes of
antiretroviral drugs are associated with potential risk of DILI,
though higher incidence has been noted for nevirapine, efavirenz
and boosted PIs [10,11]. Concomitant anti-TB and ARV therapy
exacerbates risk for DILI [12,13], and overlapping toxicity between
drugs used to treat HIV and tuberculosis could also complicate the
management. Although rifampicin (RIF) and efavirenz (EFV) are
key drugs used for concomitant TB and HIV therapy in resource
limited settings, data on the concomitant use related liver injury and
biomarkers are limited particularly from Sub-Saharan Africa, a
continent highly affected by HIV/AIDS and tuberculosis [14].
PLoS ONE | www.plosone.org 1 December 2011 | Volume 6 | Issue 12 | e27810Metabolic pathway of efavirenz is complex as being a substrate
inducer and/or inhibitor of its own metabolism involving several
CYP enzymes with varying activities [15,16]. It is primarily
biotransformed to 8-hydroxyefavirenz mainly by CYP2B6,t oa
minor extent by CYP3A [15,17]. Efavirenz and its primary and
secondary metabolites undergo conjugation mainly via UGT2B7
[17,18]. Although there are conflicting suggestions as to whether
efavirenz is a substrate for P-glycoprotein we and others have
previously reported the effect of ABCB1 genetic variation on
efavirenz pharmacokinetics [19–21]. NAT2 is the main enzyme
responsible for metabolism of isoniazid [22] and association of its
genetic polymorphism with isoniazid induced liver injury has been a
subject of exploration [23–25]. Organic anion-transporting poly-
peptide OATP1B1, coded by SLCO1B1, is a liver-specific uptake
transporter important in hepatic drug disposition. RIF is both
substrate and inhibitor of OATP1B1 [26]. All these enzymes and
transporter proteins are genetically polymorphic and inducible by
several drugs. Both RIF and efavirenz induces CYP2B6, CYP3A4,
UGT2B7, ABCB1 and SLCO1B1 [27–30]. Induction can lead to
drug–drug interactions and decreased exposure in the liver and/or
increased toxic metabolite formation. Interaction could be modified
by other anti-tubercular agents such as isoniazid which inhibits
many cytochrome P450 enzymes including CYP3A [31] and may
counter balance the inducing effect of RIF [32].
Plasma concentrations of HIV and TB drugs display wide inter-
individual variability partly due to genetic variations in the
respective drug metabolizing enzymes or transporter proteins.
Genetic variation is believed to play an important role in DILI
[23–25]. Pharmacogenetic studies of DILI is focused on the
formation of toxic and immunogenic drug metabolites, hepatobil-
iary transporters and drug metabolizing enzymes [23–25]. We
recently reported incidence as well as pharmacogenetic and
pharmacokinetic predictors of efavirenz based ART induced liver
injury in HIV only infected patients [33]. In the present study we
investigated incidence and predictors of concomitant efavirenz
based ART and rifampicin based anti-tuberculosis drugs induced
liver injury in HIV-TB co-infected patients. The present study was
designed based on the following hypotheses: i) the use of anti-
tuberculosis drugs (mainly rifampicin and isoniazid) as well as
ARV drugs is associated with liver injury. Hence concomitant uses
of these drugs exacerbate the incidence of DILI, ii) anti-
tuberculosis drugs mainly rifampicin induces CYP2B6 and CYP3A5
[27,28] lowering efavirenz plasma concentration while isoniazid
inhibits some CYP enzymes [34]. Because of drug-drug interac-
tions between anti-tuberculosis and ARV drugs, concomitant use
these drugs may present with modified genetic and kinetic
biomarkers than when used separately. Effect of genetic variations
on drug metabolizing enzymes and hepatocellular transporters
may be altered in the presence of inducers. Hence identified risk
factors for anti-tubercular or ARV therapy alone may not
represent the finding from concomitant TB-HIV therapy. To
our knowledge, no pharmacogenetic and efavirenz kinetics
association studies with respect to concomitant efavirenz based
ART and rifampicin based anti-TB DILI have been reported
previously. In the present study we performed prospective
comprehensive case-control association study for efavirenz based
antiretroviral and RIF based anti-TB DILI in HIV-TB co-infected
in Ethiopia, the second densely populated country in Africa with
1.5 million HIV infected individuals and ranks 7
th in the WHO
high TB-burden country list. Biochemical variables, efavirenz
pharmacokinetics as well as pharmacogenetic variations in six
candidate genes relevant for metabolism and transport of ARV
and anti-TB drugs; namely; CYP2B6, CYP3A5, UGT2B7, NAT2,
ABCB1 and SLCO1B1 (OATP1B1) were investigated.
Methods
Ethics Statement
The study protocol was approved by the Regional Ethical
Review Board in Stockholm at Karolinska Institutet, Sweden;
Institutional Review Board (Faculty. Research and Publication
Committee) at Faculty of Medicine, Addis Ababa University; The
National Ethics Review Committee at Ethiopian Science and
technology Ministry as well as by the Food and Drug
Administration and Control Authority of Ethiopia. Written
informed consent was obtained from each subject before the start
of this study.
Study participants
Newly diagnosed ART and anti-TB treatment naı ¨ve adult TB
and HIV co-infected patients (n=373) were recruited and enrolled
prospectively and followed up to one year during June 2007 to
January 2011. The eligibility criteria were age $18 years, CD4
count ,200 cells/UL, not pregnant and not on other known
hepatotoxic drugs concurrently (except co-trimoxazole, 960 mg
per day, which was given for all participants before enrolment and
during the follow up period according to the treatment guideline).
None of the participants received isoniazid prophylaxis and
treatment for tuberculosis two years before enrolment and during
the study period.
Treatment, clinical and laboratory investigations
All study participants received RIF based short-course chemo-
therapy for TB following the national TB treatment guideline.
ART was then initiated with 600 mg efavirenz based HAART
containing stavudine/lamivudine/efavirenz (D4T/3TC/EFV) or
zidovudine/lamivudine/efavirenz (AZT/3TC/EFV) or tenofovir/
lamivudine/efavirenz (TDF/3TC/EFV). A complete history and
physical examination were taken before enrolment and at the
scheduled and unscheduled visits. Laboratory tests were per-
formed before anti TB initiation included complete and
differential blood counts, platelet count, CD4 count, HIV RNA
determination, hepatitis B surface antigen, anti-hepatitis C
antibody, serum albumin, renal function tests, liver tests including;
aspartate aminotransferase (AST), alanine aminotransferase
(ALT), alkaline phosphatase (ALP), and direct and total bilirubin.
Follow-up for liver enzymes were performed at before and on the
1
st,2
nd,4
th,8
th,1 2
th,2 4
th,4 8
th, and 56
th weeks after initiation of
anti-TB treatment.
CYP2B6, CYP3A5 UGT2B7, ABCB1, UGT2B7 and SLCO1B1
genotyping
Blood sample was obtained from 201 patients for genotype
analysis. Genomic DNA was isolated from peripheral blood
leukocytes using QIAamp DNA Maxi Kit (QIAGEN GmbH.
Hilden. Germany). Genotyping was carried out at the division of
clinical pharmacology, Department of laboratory medicine.
Karolinska University Hospital-Huddinge, Karolinska Institute
Stockholm, Sweden.
Allelic discrimination reactions were performed using TaqManH
(Applied Biosystems, CA, USA) genotyping assays: (C__7586657_20
for ABCB1 3435C.T rs1045642, C__11711730_20 for CYP2B6
516G.T rs3745274 [CYP2B6*6] , C__30720663_20 for UGT2B7-
372G.A rs7662029 [UGT2B7*2b,*2c,*2d,*2f], C__26201809_30
for CYP3A5 6986A.G rs776746 [CYP3A5*3], C__30203950_10 for
CYP3A5 14690G.A g.14690G.A[ CYP3A5*6], C__32287188_10
for CYP3A5 g.27131_27132insT rs241303343 [CYP3A5*7],
C___1901697_20 for SLCO1B1 388A.G rs2306283 (*1b) and
C__30633906_10 for SLCO1B1 521T.C rs4149056 (*5) on ABI
Biomarkers for ART & Anti-TB Induced Liver Injury
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for each reaction was 10 ml, consisting of 26 TaqMan Universal
PCR Master MixH (Applied Biosystems), 206 drug metabolising
genotype assay mix and 10 ng genomic DNA. The PCR profile
consisted of an initial step at 50uC for 2 min and 50 cycles with 95uC
for 10 minutes and 92uCf o r1 5s e c .
NAT2 gene sequencing
The coding regions of NAT2 gene was amplified by PCR using
a forward primer (59- GTCACACGAGGAAATCAAATGC-39)
and a reverse primer (59-GTTTTCTAGCATGAAT-
CACTCTGC-39) as described previously.[35,36] The PCR
products were purified using ExoSAP-ITH (USB Corporation,
Cleveland, OH) PCR Purification kit. Sequencing was done in
forward and reverse directions using PCR primers described
above and an internal reverse primer (59-GGATGAAAGTATTT-
GATGTTTAGG-39). Sequencing reaction was done using the
ABI PRISM
TM BigDyeH terminator cycle sequencing ready
reaction kit v3.1 (Applied Biosystems, Foster City, CA), and
analyzed on an ABI Prism 377 DNA sequencer. NAT2 sequence
chromatograms were visually inspected and analyzed using
software program FinchTV version.1.4.0 (htpp://www.geospiza.
com) and aligned with the NAT2 reference sequence (http://www.
ncbi.nlm.nih.gov; GenBank reference: NM 000015.2) for SNPs
identification.
Quantification of plasma efavirenz and 8-
hydroxyefavirenz concentration
On the 4
th week of initiation of efavirenz -based HAART, 8 ml
of blood samples were collected 16 hrs post efavirenz dosing in a
vacutainer CPT (Becton Dickinson, Heidelberg, Germany) from
212 patients, centrifuged (1700 g for 20 min), and 2 mL plasma
aliquot was stored at 280uC for determination of efavirenz and its
metabolite concentrations. Plasma samples were sent in dry ice to
the Department of Clinical Pharmacology and Pharmacoepide-
miology, University of Heidelberg. Germany. Plasma efavirenz
and 8-hydroxyefavirenz concentration were determined by LC/
MS/MS as described previously [37]. The lower limits of
quantification in plasma were 10.0 ng/mL for efavirenz and
0.4 ng/mL for 8-hydroxyefavirenz. The efavirenz (8-hydroxyefa-
virenz) calibration range was 10–10000 ng/mL (0.4–400 ng/mL).
Linear regression with 1/6 weighing resulted in correlation
coefficients of r
2.0.99. Accuracy and precision (within-batch and
batch-to-batch) of the assay fulfilled all recommendations of FDA
guidelines.
Case identification
Patients with DILI were identified according to the CIOMS
(Council for International Organizations of Medical Science)
criteria, which are based on selected laboratory liver parameters
(CIOMS laboratory criteria and the exclusion of any disease-
related causes of liver injury) [38]. Liver biochemical parameters
more than two times the upper normal limit (UNL) value was
considered as DILI. Those $56 UNL or equal to threefold
elevation in ALT and simultaneous elevation of total bilirubin
concentration $26UNL were considered as severe DILI.
Statistical analysis
Baseline demographic and laboratory parameters were de-
scribed as median and interquartile range (IQR) for continuous
variables and as percentages for categorical variables. Chi-square
test was used to compare the observed and expected allele
frequencies according to Hardy-Weinberg equilibrium. Haplotype
analysis was done using Haploview v.4.1 software. The efavirenz
metabolic ratio (EFV MR) was calculated by dividing concentra-
tions of efavirenz by 8-hydroxyefavirenz. Normality of kinetic data
was assured by transforming the data to Log 10 values before
statistical analysis. Independent t-test was used to compare log
transformed plasma efavirenz, 8-hydroxyefavirenz and efavirenz/
8-hydroxyefvarinz ratio between patients with and without DILI.
Univariate and multivariate Cox proportional Hazards Model
were performed to identify potential predictors of DILI and
Kaplan-Meier curves was performed to estimate the incidence of
DILI over time. Incidence of DILI was calculated as the number
of episodes per 1000 persons exposed per week. SPSS version 19.0
for complete data analysis and Statistica version 10 for graphical
data presentation were employed. Variables with p,0.05 were
considered potential predictors for DILI.
Results
A total of 373 newly diagnosed antiretroviral and antitubercular
treatment naı ¨ve HIV-TB co-infected patients among which 199
(53.4%) women and 174 (46.6%) men were enrolled prospectively
and followed up for development of DILI for up to 56 weeks after
initiation of antiTB treatment. Twenty patients (20.4%) were
excluded from the analysis and put on standard treatment as per
the national guideline for they had elevated transaminases
(.56UNL) before starting efavirenz therapy. The remaining
353 patients were initiated with the four fixed dose combination
anti TB drugs namely rifampicin, ethambutol, pyrazianmide and
isoniazid for the intensive phase (2-month) followed with isoniazid
and rifampicin for the continuation phase (4-month). All patients
were also initiated with either AZT/3TC/EFV or D4T/3TC/
EFV or TDF/3TC/EFV within the first 8 weeks after starting
anti-TB treatment.
Baseline characteristics of patients
The median age of participants was 35 years (range 18–72) and
49.2% of them had a BMI of ,18.5. Seventy eight patients were
diagnosed smear positive TB; while 62, 36, and 177 smear negative,
disseminated and extra pulmonary TB, respectively. Screening of
participants for Hepatitis B and C showed that 33 (9.3%) were
positive for Hepatitis B surface antigen, while 5 (1.4%) was positive
for Hepatitis C virus antibody. Association of socio demographic
parameters, sex and type of HAART with DILI using Cox-
regression analysis is presented in Table 1. Association of DILI with
female sex (p=0.001) and lower BMI (p=0.09) was noted.
Incidence and timing for ART and anti-TB DILI
From a total of 353 patients, 106 (30.0%) or 14.5 per 1000
person-week developed DILI. The median time for development
of DILI was 2 weeks and the majority (91.6%) of the DILI
occurred during the first 8 weeks. Severe DILI, i.e., elevation of
transaminases .5 times the upper normal limit was observed in 65
participants (18.4%) or 7.49 per 1000 person-week. During the
follow up period 12.7% died among which 44.7% had DILI and
only 5% had severe DILI before they died but none of the deaths
in our cohort were secondary to liver failure. From the total of 65
patients who developed severe DILI 26 (40.4%) were taking
D4T30/3TC/EFV (Table 1), There was no significant differences
in the incidence of DILI between patients who received D4T and
those who did not.
Pharmacokinetic and biochemical predictors of DILI
Analysis of baseline biochemical characteristics and efavirenz
kinetics with development of DILI is presented in Table 2. There
Biomarkers for ART & Anti-TB Induced Liver Injury
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sex, having lower baseline hemoglobin, lower albumin, elevated
baseline AST and ALT level, increased plasma efavirenz
concentration and efavirenz/8-OH efavirenz metabolic ratio with
p values of 0.001, 0.008, 0.007, 0.022, 0.014, 0.009, and 0.036,
respectively. Comparison of mean log plasma efavirenz, 8-
Table 1. Association of socio demographic parameters of study participants and type of therapy with DILI.
Efavirenz-based ART DILI Hazard ratio (95%CI) p-value
Cases
=65)
Cases
=65)
Sex 0.001
Female (%) 39 (60.0) 148 (51.4)
Male (%) 26 (40.0) 140 (58.6) 0.43 (0.26–0.71)
Body mass index 0.09
,=18.5 (%) 37 (56.3) 132 (45.8)
.18.5 (%) 28 (43.8) 156 (54.2) 0.66 (0.40–1.07)
Hepatitis C virus antibody 0.49
Positive (%) 1 (1.5.0) 4 (1.4%)
Negative (%) 64 (98.5) 284 (98.6) 0.68 (0.62–0.73)
Hepatitis B surface antigen 0.79
Positive (%) 5 (7.7) 28 (9.7)
Negative (%) 60 (92.3) 260 (90.7) 1.1 (0.46–2.76)
Marital status 0.51
Married (%) 21 (32.3) 106 (36.8)
Divorced (%) 11 (16.7) 43 (14.9)
Single (%) 22 (34.4) 107 (37.3)
Widowed (%) 11 (16.7 31 (10.9)
Type of HAART 0.69
D4T30/3TC/EFV (%) 26 (40.4) 98 (34.1)
CBV/EFV (%) 23 (34.8) 114 (39.6)
TDF/3TC/EFV (%) 16 (24.8) 76 (26.4)
doi:10.1371/journal.pone.0027810.t001
Table 2. Comparison of median and inter quartile range of pre-treatment biochemical variables, liver chemistry tests and efavirenz
kinetics between TB/HIV co-infected patients who developed anti-TB and efavirenz based HAART induced sever liver injury and
who did not using Cox regression analysis.
Parameters Anti TB and EFV based ART DILI P Exp(ß) 95.0% CI for Exp(ß)
Yes No Lower Upper
Log EFV (ng/mL) 3.42 (3.04–3.71) 3.12(2.99–3.30) 0.004 4.568 1.610 12.965
Log 8-OH EFV (ng/mL) 2.00 (1.79–2.16) 1.95 (1.79–2.25) 0.65 0.768 0.240 2.453
Log EFV MR 1.44 (1.02–1.95) 1.17 (0.88–1.49) 0.012 2.45 1.214 4.954
Hemoglobin 10.8 (9.4–11.7) 11.5 (10.0–12.9) 0.008 0.877 0.796 9.666
AST (U/L) 71.0 (39–110) 40.0 (32–61) 0.022 1.012 1.002 1.023
ALT (U/L) 62.0 (39.0–111) 42 (32–61) 0.014 1.011 1.002 1.020
ALP (U/L) 158 (110–240) 116 (91–159) 0.124 1.002 0.999 1.004
total bilirubin (mmol/L) 0.49 (.30–.89) 0.46 (.31–.87) 0.972 0.991 0.609 1.614
direct bilirubin (mmol/L) 0.05 (.05–.24) 0.05 (0.5–.19) 0.182 2.456 0.657 9.180
Serum albumin 3.4 (2.9–3.9) 3.7 (3.2–4.1) 0.007 0.666 0.494 0.897
Urea 25.0 (20.0–31.0) 27 (20–33) 0.540 0.995 0.978 1.012
serum creatinine mmol/L 0.90 (.70–1.05) 0.9 (.8–1.1) 0.374 0.675 0.284 1.606
CD4 count/mL 75 (47–127) 96 (50–137) 0.073 0.996 0.992 1.000
Log plasma viral load 5.12 (4.26–5.64) 5.03 (4.51–5.50) 0.397 1.137 0.845 1.531
doi:10.1371/journal.pone.0027810.t002
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patients who developed DILI and who did not is presented
Figure 1.
NAT-2, CYP2B6, CYP3A5, ABCB1, UGT2B7*2, and
SLCO1B1 genotype and development of DILI
Out of the 353 participants who were included in the
association analysis, genotyping for NAT-2, CYP2B6, CYP3A5,
ABCB1, UGT2B7*2, and SLCO1B1 genotype was done for 201.
Association of each genotype with development of sever DILI is
presented in Table 3. Frequency distribution of NAT2 genotype,
alleles and deduced phenotype between DILI cases and controls is
presented in Table 4. NAT2 haplotypes were determined using
Haploview following the nomenclature described in http://
louisville.edu/medschool/pharmacology/NAT.html. According
to the NAT2 genotypes, all participants were stratified into rapid
(carrier of NAT2*4, *12 or *13) and slow (homozygous for the
defective variant allele NAT2*5, *6 or *7 or combination there off).
NAT2 genotypic analysis of the different SNPs showed that 138
(68.7%) patients were slow acetylators, while 63 (31.3%) were
rapid acetylators. NAT2 rapid acetylator genotype was a
significantly reduced the risk of developing DILI. None of the
patients who developed DILI were homozygous for functional
NAT2 variant allele (p,0.05). Cox-regression analysis showed that
there was a statistically significant association DILI with
CYP2B6*6 and ABCB1 3435TT genotype (Table 3). There was
significant difference in the proportion of subjects with ABCB1
3435TT genotype between cases and controls being higher in
those who developed DILI. A nearly significant effect of
UGT2B7*2/*2 genotype with DILI was noted.
Discussion
We performed a prospective case-control association study to
identify incidence, and potential biochemical, pharmacokinetic
and pharmacogenetic biomarkers for concomitant ARV and anti-
TB drugs induced liver injury in TB-HIV co-infected patients
receiving efavirenz based for anti retroviral and RIF based anti-
TB drugs. We found a higher incidence of ARV and anti-TB
DILI, with the median time to event being two weeks after
initiation of anti-TB therapy. The result indicates association of
elevated serum efavirenz plasma concentration, baseline AST and
ALT level, lower baseline hemoglobin and albumin level with
DILI. Pharmacogenetic analysis for common functional variant
alleles in six relevant drug metabolizing and/or transporter genes
namely NAT2, CYP2B6, CYP3A5, ABCB1, UGT2B7, and SLCO1B1
were done. ABCB1 3435TT, CYP2B6*6/*6 and slow NAT2
acetylators genotypes were identified as pharmacogenetic bio-
markers for the development of ARV and anti-TB DILI in
Ethiopian TB-HIV co-infected patients. To our knowledge this is
the first study to extensively examine effects of pharmacogenetic
variations in several relevant genes coding for ARV and anti-TB
drugs metabolizing enzymes and transporter proteins as well as to
investigate impact of between patient variability in systemic
efavirenz exposure and baseline biochemical parameters on risk
for development of DILI with a longer follow-up period.
The incidence of DILI in the present study is higher than what
we reported previously for anti-TB alone [39] or EFV based ART
alone in Ethiopians patients [29]. Our result is in agreement with
the previous reports describing concomitant ART and anti-TB
therapy exacerbates the incidence of DILI [12,13,40–42]. Given
the fact that HIV and TB therapy consist of cocktail of drugs with
potential drug-drug interactions, the adverse events profile of each
drug could be modified or adds up during concomitant therapy.
In general, drugs used to treat HIV and TB infections are
known to induce drug-metabolizing enzymes and transporter
proteins. Induction might also lead to increased production of
deleterious reactive intermediates and reactive oxygen species.
Mechanism for combined anti-retroviral and anti-TB DILI
remains elusive and is beyond the scope of the present study.
Our finding indicates high efavirenz level as a possible biomarker
and risk factor for DILI. RIF induces CYP2B6 and CYP3A
lowering EFV plasma concentration [43]. Consequently concom-
itant RIF therapy should lower the risk for EFV induced liver
injury. Our previous [29] and present study indicate the
association of higher EFV plasma concentration with DILI
Figure 1. Comparison efavirenz pharmacokinetics between
DILI cases and controls: mean log transformed plasma
efavirenz (ng/mL). 8-hydroxyefavirenz (ng/mL) and efavirenz/8-
hydroxyefavirenz ratio (MR) was compared between patients who
developed concomitant efavirenz-based HAART and rifampicin based
anti-tubercular drugs induced liver injury (cases) and those who did not
(controls).
doi:10.1371/journal.pone.0027810.g001
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association of the metabolite (8-hydroxyefvairenz) was observed
(Figure 1). However concomitant rifampicin administration has
not been shown to constantly reduce efavirenz concentration [44–
46]. Alternatively inhibition of CYP enzymes by isoniazid could
modulate the inducing effect of RIF [32]. Nevertheless, we noted
significant association between having higher plasma efavirenz
concentration and DILI not only in absence but also in the
presence of rifampicin base anti TB therapy as well.
The high efavirenz plasma level in patients who developed DILI
might be the result of impaired efavirenz metabolism due to liver
injury caused by other factors. Alternatively direct liver toxicity by
higher efavirenz plasma concentration could be a possible
mechanism for efavirenz-based HAART induced liver injury in
HIV patients. Association of DILI with CYP2B6*6 and UGT2B7*2,
variant alleles associated with increased efavirenz plasma concen-
tration, [19,47] supports the later argument. In line with this, there
is evidence that efavirenz reduces cellular proliferation and triggers
apoptosis in vitro. Clinically relevant concentration of EFV is shown
to be mitotoxic in human hepatic cells in a concentration-
dependent manner, pertinent to direct efavirenz induced hepato-
toxicity [48]. A recent study reported that increased efavirenz level
exceeding a certain threshold of mitochondrial dysfunction is
associated with an autophagic overload or stress and may
constitute a new mechanism implicated in the pathogenesis
efavirenz induced liver damage. [49].
Isoniazid is inactivated by NAT2 in the liver resulting in
acetylisoniazid, which is further hydrolyzed to monoacetylhydra-
zine (MAH) [50]. Earlier studies suggested that fast acetylators
were at higher risk for liver injury because they generated more
acetyl-isoniazid, which could be further metabolized to other toxic
intermediaries [51,52]. However, fast acetylators clear MAH more
rapidly and hence slow acetylators may have greater cumulative
MAH exposure. Increased susceptibility to DILI among slow
acetylators [53–56] or a lack of correlation with acetylation rate
has been reported [57–59]. We found that slow acetylation status
is the predominant phenotype in Ethiopian TB-HIV co-infected
patients as the majorities (68%) of patients were homozygous for
the defective variant allele. Therefore we classified patients having
at least one functional variant allele as rapid acetylator genotype
Table 3. Association of CYP2B6, CYP3A5, NAT2, UGT2B7, SLCO1B1 and ABCB1 genotype/haplotype genes with development of
concomitant anti-TB and efavirenz based ART induced liver injury using cox regression analysis.
Genotype Anti TB and EFV based ART DILI P Exp(B) 95.0% CI for Exp(B)
Cases (n=41) Controls (n=160) Lower Upper
CYP2B6 516 G.T (*6)
GG 16 (38.7%) 79 (49.6%)
GT 19 (46.8%) 66 (41.0%) 0.07 2.339 0.917 5.969
TT 6 (14.5%) 15 (9.4%) 0.04 2.054 1.045 4.037
ABCB1 3435C.T
CC 29 (70.7%) 99 (61.9%)
CT 7 (17.1%) 55 (34.4%) 0.38 0.593 0.183 1.928
TT 5 (12.2%) 6 (3.8%) 0.02 5.276 1.210 22.998
Number of CYP3A5*1
Two 2 (4.9%) 9 (5.6%)
0ne 17 (41.5%) 50 (31.3%) 0.67 0.673 0.317 5.936
Zero 22 (53.7%) 101 (63.1%) 0.93 0.944 0.222 4.014
NAT2 acetylators*
Slow 31 (75.6%) 107 (66.9%)
Rapid 10 (24.4%) 53 (33.1%) 0.039 0.377 0.15 0.95
UGT2B7 -372G.A
GG 5 (12.2%) 36 (22,5%)
GA 22 (53.7%) 86 (53.8%) 0.26 1.735 0.660 6.762
AA 14 (34.1%) 38 (23.8%) 0.08 1.735 0.657 4.583
SLCO1B1 388A.G (*1b)
GG 15 (36.6%) 53 (33.1%)
AG 17 (41.5%) 87 (54.4%) 0.74 .891 0.450 1.765
AA 9 (22.0%) 20 (12.5%) 0.38 1.464 0.0617 3.474
SLCO1B1 521T.C (*5)
TT 27 (65.9%) 107 (66.9%)
TC 13 (31.7%) 49 (30.6%) 0.67 1.153 0.599 2.220
CC 1 (2.4%) 4 (2.5%) 0.92 .901 0.116 7.020
*see table 4 for detail NAT-2 allele and genotype frequency distribution.
Contrast analysis within each genotype group was done using one of the genotype as indicator reference. For the NAT2 genotypes, subjects were stratified into rapid
(carrier of NAT2*4, *12 or *13) and slow (homozygous for NAT2*5, *6, *7 or combination there off) acetylators.
doi:10.1371/journal.pone.0027810.t003
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significantly lowers the risk for DILI. Our finding is in line with the
recent report where HIV-positive patients that have the slow
acetylation profile are significantly associated with a higher risk of
developing liver toxicity due to anti-TB drugs [56].
Several anti TB drugs and antiretroviral drugs and are
substrates of P-glycoprotein, coded by ABCB1 gene. We found
association of ABCB1 3435TT genotype with increased risk for
development of DILI. Interestingly the proportion of patients
homozygous for ABCB1 3435TT genotype was three fold higher in
the patients who developed DILI compare to those who did not.
ABCB1 is responsible for the transport of many antiretroviral and
anti tuberculosis drugs including rifampicin and ethambutol.
ABCB1 3435T variant allele is reported to lower expression level
and protein folding thereby altering the structure of substrate
binding sites to and decreased transport activity [60]. Result from
the present study indicates that this SNP may be associated with
predisposition to ART and rifampicin based anti-TB DILI
through a possible low transport activity.
Apart from pharmacogenetic and pharmacokinetic predictors,
our result indicates a strong association between development of
DILI and baseline elevation in serum aminotransferases as seen in
other studies indicating that pretreatment liver enzymes are good
predictors for development of DILI. The median time for
development of DILI was two weeks, and 91.6% occurred during
the first 8 weeks of follow up. This finding has clinical importance
in providing information when to frequently assess this group of
patients for development of DILI. Five of the patients who
discontinued treatment because of severe DILI restarted their anti-
TB treatment successfully (none discontinued HAART).
In summary, we report higher incidence of concomitant anti-
tubercular and efavirenz based ARV DILI among Ethiopian TB-
HIV co-infected patient The identified predictors include; slow
acetylation status, CYP2B6*6/*6 and ABCB13435TT genotype,
elevated baseline liver aminotransferases, high plasma efavirenz
concentration, lower hemoglobin and albumin levels. Our result
demonstrates that inter-patient variability in systemic efavirenz
exposure and pharmacogenetic variation in NAT2, CYP2B6 and
ABCB1genedetermines susceptibilitytoefavirenz induced liver injury
in HIV patients and patients. Close follow up and regular monitoring
of plasma efavirenz concentration and liver enzymes during early
therapy is recommended, particularly in patients with the described
underlying risk factors for early diagnosis and management of
efavirenz-based HAART induced liver injury. Therapeutic drug
monitoring may not be feasible in resource limited setting. Therefore
genotyping practice for common functional variants of NAT2,
CYP3A5 and CYP2B6 gene in HIV clinics before initiation of therapy
is recommended to identify susceptible individuals and optimize the
safety of concomitant rifampicin based anti-TB and efavirenz based
antiretroviral therapy in co-infected patients.
Table 4. Frequency distribution of NAT2 genotype and alleles and deduced phenotype (according to the NAT-2 nomenclature;
http://louisville.edu/medschool/pharmacology/NAT2.html) between patients who developed concomitant efavirenz based ARV
and rifampicin based anti-tuberculosis drug induced liver injury (DILI Yes) and who did not (DILI No).
NAT2 deduced phenotype NAT2 genotype/allele DILI Total
No Yes
NAT2 genotype
Rapid *4/*4 2 (1.3%) 0 2
*4/*12 2 (1.3%) 0 2
*4/*13 2 (1.3%) 0 2
*12/*12 3 (1.9%) 0 3
*13/*13 1 (0.6%) 0 1
*4/*5 6 (3.8%) 2 (4.9%) 8
*4/*6 11 (6.9%) 2 (4.9%) 13
*5/*12 15 (9.4%) 3 (7.3%) 17
*5/*13 1 (0.6%) 1 (2.4%) 2
*6/*12 9 (5.6%) 0 (0) 9
*6/*13 1 (0.6%) 2 (4.9%) 3
Slow *5/*5 33 (20.6%) 9 (22.0%) 43
*5/*6 39 (24.4%) 13 (31.7%) 52
*5/*7 8 (5.0%) 1 (2.4%) 9
*6/*6 23 (14.4%) 7 (17.1%) 30
*6/*7 4 (2.5%) 1 (2.4%) 5
NAT2 alleles
Rapid *4 (reference) 7,80% 4,90% 7,20%
*12 (803A.G, rs1208) 10,00% 3,70% 8,50%
*13 (282C.T, rs1041983) 1,90% 3,70% 2,20%
Slow *5 (341T.C,rs1801280) 42,20% 46,30% 43,30%
*6 (590G.A, rs1799930) 34,40% 39,00% 35,30%
*7 (857G.A, rs1799931) 3,80% 2,40% 3,50%
doi:10.1371/journal.pone.0027810.t004
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